On June 10, 2020, the team from Vanguard teamed up with Canna Advisors and Rymedi to once again welcome hundreds of guests from around the globe for another episode of our webinar series on forthcoming FDA regulation, and GMP compliance for domestic market and export-readiness in the hemp extraction, processing, and manufacturing industry...
On April 22, 2020, the team from Vanguard welcomed hundreds of guests from around the globe for the first episode of Vanguard Scientific's 2020 webinar series on forthcoming FDA regulation for the hemp extraction, processing, and manufacturing industry...
On March 5th, the Food and Drug Administration released their most recent commentary on cannabidiol regulation, with a stated focus on protecting public health and providing market clarity. Arriving more than a month after its expected delivery date, the congressional report offered little in the way of material guidance for an industry frustrated by its unending purgatorial wait. Now, with little to work against in terms of timelines or anticipated regulatory requirements, the industry is left staring across international and industry borders to attempt to define its future.